Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 4/20 | 0.48 |
| ▸ | WDR5 | P61964 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560292 | 0.92 | PTK2B (0.50) | SLC16A3LMNAPTK2BTHRBFABP4 | |
| SCHEMBL3557793 | 0.92 | SLC16A3 (0.56) | SLC16A3LMNAPTK2BTHRBFABP4 | |
| SCHEMBL3560333 | 0.88 | PTK2B (0.60) | SLC16A3LMNAPTK2BFABP4WDR5 | |
| SCHEMBL3556737 | 0.87 | SLC16A3 (0.53) | SLC16A3LMNAPTK2BFABP4FABP5 | |
| SCHEMBL3556263 | 0.87 | SLC16A3 (0.74) | SLC16A3LMNAPTK2BTHRBWDR5 | |
| SCHEMBL5164879 | 0.85 | SLC16A3 (0.54) | SLC16A3LMNAPTK2BTHRBPOLB | |
| SCHEMBL3552762 | 0.85 | SLC16A3 (0.78) | SLC16A3LMNAPTK2B | |
| SCHEMBL3555622 | 0.85 | SLC16A3 (0.72) | SLC16A3LMNATHRBPOLBHTR6 | |
| SCHEMBL3556551 | 0.84 | THRB (0.65) | SLC16A3LMNATHRBPOLBHTR6 | |
| SCHEMBL3556603 | 0.83 | SLC16A3 (0.52) | SLC16A3LMNAPTK2BTHRBHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885LMNA 2120/4885PTK2B 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.